<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Combination therapy with <z:chebi fb="0" ids="42068">idarubicin</z:chebi> plus continuous-infusion, high-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> in patients with newly diagnosed <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> resulted in an improved complete response rate over historic controls who received either (1) Adriamycin or <z:chebi fb="0" ids="2687">amsacrine</z:chebi> in combination with standard-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> or (2) continuous-infusion, high-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> alone or in combination with <z:chebi fb="0" ids="2687">amsacrine</z:chebi> or <z:chebi fb="0" ids="50729">mitoxantrone</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>The complete response rate in patients with <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> was similar to that in patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts in transformation </plain></SENT>
</text></document>